4. Total walking distance data for comparisons of pentoxifylline versus other treatments.

Study Other treatment	Dose	Dur	Pxt	Oth	Px0	SD	Px‐E	SD	%age	Oth0	SD	Oth‐E	SD	%age	Diff
Accetto 1982 Nylidrin hydrochloride	1200	8	23	24	132.6	—	193.4	—	45.9	163.4	—	168.9	—	3.4	42.5
Bohmer 1988 Gingko biloba	1200	24	13	14	189.5	—	427.3	—	125.5	203	—	436.5	—	115.0	10.5
Chacon‐Quevedo 1994 Buflomedil	1200	13	15	15	180	67	226	57	25.6	159	76	205	66	28.9	–3.3
Chacon‐Quevedo 1994 Nifedipine	1200	13	15	15	180	67	226	57	25.6	186	54	226	49	21.5	4.1
Ciocon 1997 Aspirin	1200	6	45	45	1 mile	—	2 miles	—	100	0.8 miles	—	1.2 miles	—	50	50
Creager 2008 Iloprost*	1200	24	86	87	—	—	—	—	13.9	—	—	—	—	11.2	2.7
Dawson 2000 Cilostazol	1200	24	232	227	238	119	308	183	29.4	241	123	350	209	45.2	–15.8
Hepp 1992 Prostaglandin E1	400	4	98	97	115	—	190	—	65.2	129	—	230	—	78.3	–13.1
Lee 2001a Cilostazol	800	8	17	17	114	51	147	81	28.9	111	30	145	53	30.6	–1.7
Perhoniemi 1984 Flunarizine cross‐over	1200	12	31	31	255	—	—	—	18	255	—	—	—	43	–25
Schellong 2012 PGE1	1200	8	285	276	—	—	1.76**	1.78	—	—	—	1.64**	0.86	—	—

*highest dose group iloprost.
**Total walking distance reported as ratio of distance after eight weeks of treatment compared with baseline.

Dur: duration in weeks.
Pxt: pentoxifylline sample size.
Oth: other treatment group sample size.
Px0: baseline walking distance in metres for pentoxifylline group.
SD: standard deviation.
Px‐E: end walking distance in metres for pentoxifylline group.
%age: percentage improvement in walking distance.
Oth0: baseline walking distance in metres for other treatment group.
Oth‐E: end walking distance in metres for other treatment group.
Diff: difference in percentage improvement for pentoxifylline and other treatment groups.